Inhibit the Attachment of Influenza A Virus

Andrea Derksen1, Andreas Hensel1, Wali Hafezi2, Fabian Herrmann3, Thomas J. Schmidt1,
Christina Ehrhardt3, Stephan Ludwig3, Joachim Kühn2*

1 Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Münster, Germany, 2 Institute of Medical Microbiology - Clinical Virology, University Hospital Münster, Münster, Germany, 3 Institute of Molecular Virology, University of Münster, Münster, Germany

Abstract

Infections by influenza A viruses (IAV) are a major health burden to mankind. The current antiviral arsenal against IAV is limited and novel drugs are urgently required. Medicinal plants are known as an abundant source for bioactive compounds, including antiviral agents. The aim of the present study was to characterize the anti-IAV potential of a proanthocyanidin-enriched extract derived from the aerial parts of Rumex acetosa (RA), and to identify active compounds of RA, their mode of action, and structural features conferring anti-IAV activity. In a modified MTT assay, RA was shown to inhibit growth of the IAV strain PR8 (H1N1) and a clinical isolate of IAV(H1N1)pdm09 with a half-maximal inhibitory concentration (IC50) of 2.5 µg/mL and 2.2 µg/mL, and a selectivity index (SI) (half-maximal cytotoxic concentration (CC50)/IC50) of 32 and 36, respectively. At RA concentrations >1 µg/mL plaque formation of IAV(H1N1)pdm09 was abrogated. RA was also active against an oseltamivir-resistant isolate of IAV(H1N1)pdm09. TNF-α and EGF-induced signal transduction in A549 cells was not affected by RA. The dimeric proanthocyanidin epicatechin-3-O-gallate-(4→8)-epicatechin-3′-O-gallate (procyanidin B2-di-gallate) was identified as the main active principle of RA (IC50 approx. 15 µM, SI>13). RA and procyanidin B2-di-gallate blocked attachment of IAV and interfered with viral penetration at higher concentrations. Galloylation of the procyanidin core structure was shown to be a prerequisite for anti-IAV activity; o-trihydroxylation in the B-ring increased the anti-IAV activity. In silico docking studies indicated that procyanidin B2-di-gallate is able to interact with the receptor binding site of IAV(H1N1)pdm09 hemagglutinin (HA). In conclusion, the proanthocyanidin-enriched extract RA and its main active constituent procyanidin B2-di-gallate protect cells from IAV infection by inhibiting viral entry into the host cell. RA and procyanidin B2-di-gallate appear to be a promising expansion of the currently available anti-influenza agents.

Introduction

Influenza A and B viruses (IAV, IBV) circulating in the human population are responsible for seasonal epidemics of varying extent. At present, the global annual disease burden of seasonal influenza is estimated to be 1 billion infections, 3 to 5 million of severe infections, and 300 000 to 500 000 fatalities. Without doubt, vaccination remains the most important strategy for prophylaxis and control of seasonal influenza [1]. Although predominantly associated with mild symptoms of upper respiratory tract infection, the first pandemic of the 21st century caused by IAV(H1N1)pdm09 impressively demonstrated the global health risks associated with IAV. Ongoing zoonotic infections with avian IAV(H3N1) and (H7N9) in the human population underscore the permanent threat of pandemic outbreaks, of which the “Spanish flu” pandemic of 1918–19 with an estimated number of 30 million deaths world-wide has been the most devastating [2].

Two classes of antiviral drugs have been licensed for the treatment and prophylaxis of influenza [3]. Matrix protein inhibitors, such as amantadine and rimantadine, inhibit viral uncoating. They are ineffective against IBV and are currently not recommended for the treatment of IAV infections due to high levels of resistance [4]. Neuraminidase inhibitors (NAI), such as oseltamivir and zanamivir, inhibit the release of virus progeny from infected cells and viral spread, are effective against IAV and IBV and have been licensed for first-line therapy of influenza. Although the vast majority of currently circulating IAV(H3N2) and (H1N1)pdm09 is sensitive to oseltamivir, the widespread use of oseltamivir has led to a high level of IAV(H1N1) resistance in 2008–9 [3,5]. In IAV(H1N1)pdm09 resistance against oseltamivir is almost exclusively caused by a single amino acid exchange (H275Y) in the neuraminidase [6]. Recently, two novel NAIs have been approved for the treatment of influenza, peramivir and lanamivir octanoate, the latter being effective also against oseltamivir-resistant influenza virus strains [3,7]. Since monotherapy with each of the NAIs currently licensed may eventually lead to the selection of resistant virus, drug combinations directed against different molecular targets of influenza virus may be a promising strategy to delay the development of resistance and to
achieve synergistic effects. Thus, novel viral targets, antiviral agents and therapeutic strategies such as inhibitors of the viral RNA polymerase complex and broadly neutralizing antibodies should be developed and utilized for the treatment and prophylaxis of influenza [8,9].

Medicinal plant extracts with anti-IAV activity have been described in many publications [10–12]. Although in most plant-derived preparations active compounds and structure-activity relationships remain to be elucidated, polyphenols have been frequently identified to be the antiviral principle in plant extracts [13]. In particular, the broad antiviral and antimicrobial activity of green tea and its components has received much attention [14, 15]. In green tea and a number of other polyphenol-rich plant extracts, catechins and proanthocyanidins, a subgroup of polyphenols derived from oligomeric flavan-3-ols, were found to exert antiviral effects against influenza viruses and other enveloped and non-enveloped viruses [16–20]. Recently, we have shown inhibition of viral attachment of herpes simplex virus type-1 by proanthocyanidin-enriched extracts from Rumex acetosa L. (Polygonaceae) and Myrothamnus flabellifolia Welw. [21, 22]. Extracts from R. acetosa are a component of modern phytotherapeutical preparations with nationally registered drug status in Europe, and are used in the treatment of acute and chronic respiratory viral infections [23].

Aim of the present study was to investigate the anti-IAV activity of the R. acetosa extract (RA) in vitro, to identify relevant compounds and structural requirements for anti-IAV activity and to characterize their mode of action. Our results show that RA strongly inhibits growth of IAV by blocking viral entry. The dimeric, digalloylated procyanidin epicatechin-3-O-gallate-(4β–8)-epicatechin-3’-O-gallate (syn. procyanidin B2-di-gallate) was identified as main active principle in RA. Galloylation of the procyanidin backbone was found to be a prerequisite for anti-IAV activity.

Materials and Methods

Plant material, extract and isolated compounds of Rumex acetosa

Starting materials and preparation of the Rumex acetosa L. extract RA have been described recently [21]. Isolation and analytical characterization of proanthocyanidins from RA have been reported by Bicker et al. (2009) [24]. Structural features, sources and purity of flavan-3-ols, oligomeric proanthocyanidins, hydrolyzable tannins, depsides and building blocks of tannins used for antiviral bioassays used in this study are given in Figure 1 and Table 1. Sodium heparin (100,000 IU/g) was purchased from Roth (Karlsruhe, Germany).

Cells and viruses

MDCK II cells (canine kidney cells) were propagated in minimal essential medium (MEM; Biochrom, Berlin, Germany) supplemented with 5% fetal calf serum (FCS; Biochrom), 2 mM L-glutamine (Sigma-Aldrich), non-essential amino acids (1×) and 100 μg/mL penicillin/streptomycin (Biochrom). A549 cells (human lung epithelial cells) were grown in DMEM (PAA Laboratories, Pasching, Austria), supplemented with 10% FCS and 100 μg/mL penicillin/streptomycin. Cytotoxicity, antiviral and penetration assays (see below) were performed using serum-free media.

The influenza A virus laboratory strain A/Puerto Rico/8/34 (PR8), and three clinical isolates of IAV[H1N1]pdm09, i.e., A/ Nordrhein-Westfalen/172/09 (NRW172), A/Nordrhein-Westfalen/173/09 (NRW173) [25] and isolate 1/09 (I1) obtained at the Institute of Medical Microbiology – Clinical Virology, University Hospital Münster, were propagated in embryonated chicken eggs. Viral stocks were prepared as described elsewhere [26].

The number of infectious particles in viral stocks was assessed by plaque titration. MDCK II cells were infected with serial dilutions of IAV in PBS containing 0.21% bovine albumin (MP Biomedicals, Eschwege, Germany), 100 U/mL penicillin (Biochrom), 100 μg/mL streptomycin (Biochrom), 230 μmol/L MgCl2 (Roth) and 514 μmol/L CaCl2 (Roth) for 30 min. at 37°C (500 μL/well). After discarding the inoculum, cells were washed with PBS and covered with 2 mL of overlay medium (MEM [Gibco, Life Technologies, Darmstadt, Germany] containing 100 U/mL penicillin, 100 μg/mL streptomycin, 0.21% NaHCO3 [Gibco], 0.01% DEAE-dextran hydrochloride [Sigma-Aldrich], 0.21% bovine albumin, 232 μmol/L MgCl2, 518 μmol/L CaCl2, 0.0061 % trypsin/829 nmol/L EDTA [Biochrom] and 0.62% Avicel type RC-591 NF [FMC BioPolymer, Philadelphia, PA, USA]). After 48 h of incubation at 37°C, overlay medium was discarded, cells were washed with PBS, fixed with 3.7% formaldehyde for 10 min. and stained with 0.1% crystal violet for 15 min. Subsequently, virus plaques were counted and the infectious titer (pfu/mL) was calculated.

Cytotoxicity assay, antiviral assays

Cytotoxicity assay. The effect of RA and its components on the proliferation of MDCK II cells was determined in 96-well plates (TPP, Trasadingen, Switzerland) using the MTT assay [27] essentially as described by Gescher et al. (2011) [21] with the exception that samples were incubated at 37°C for 1 h prior to addition to cells and remained on the cells for 48 h. The cytotoxic concentration of RA or its components which reduced the cells’ viability by 50% (IC50) was determined from dose-response curves. The untreated control was arbitrarily set as 100%.

MTTIAV assay. The inhibitory effects of RA and other test compounds on the cytopathic effect induced by IAV replication was determined in a MDCK II cell-based assay measuring cell viability by MTT stain (MTTIAV assay) [28]. An inoculum of 1 × 10^4 pfu IAV/well (corresponding to a multi plidity of infection of 0.1) was used to infect 96-well plates. All incubation steps were performed with serum-free MEM. In the elementary assay, IAV was pre-incubated with test compounds for 1 h at 37°C and subsequently MDCK II cells were incubated with this RA/IAV mixture for 48 h. In modified assays, either the test compound/IAV mixture was removed from the cells after 60 min., or cells were pre-incubated with test compounds alone for 1 h prior to infection with IAV, or test compounds were added to the cells following a 1 h infection period with IAV.

The antiviral activity was calculated according to the following formula [29]:

\[
\text{antiviral activity} (\%) = \left(\frac{OD_{\text{IAV}}}{OD_{\text{mock}}} - 1\right) \times 100
\]

ODIAV represents the optical density of cells, which were infected by IAV (index: IAV) and treated with RA. ODIAV corresponds to the optical density measured for the untreated IAV-infected cells and ODmock is the optical density of untreated, mock-infected cells. The antiviral dose of RA which protected the cells by 50% was defined as the 50% inhibitory concentration (IC50).

Plaque reduction assay. IAV was incubated with antiviral compounds for 1 h at 37°C, both diluted in PBS containing 100 U/mL penicillin, 100 μg/mL streptomycin, 230 μmol/L...
MgCl₂ and 514 μmol/L CaCl₂. MDCK II cells, cultivated in 12-well culture plates (Greiner Bio-One, Frickenhausen, Germany), were washed with PBS and infected with 300 μL/well IAV/RA-suspension (100 pfu/well). After 30 min. of incubation, the inoculum was removed, 1 mL of overlay-medium without bovine albumin was added and the plates were cultivated for 72 h at 37°C. Subsequently, cells were stained as described above, virus plaques were counted and antiviral activity was calculated by the following formula [21]:

**Figure 1. Structural features of flavan-3-ols, oligomeric proanthocyanidins, hydrolyzable tannins, depsides and building blocks of tannins tested for antiviral activity; compounds isolated from *Rumex acetosa* extract RA are marked by asterisk.**

doi:10.1371/journal.pone.0110089.g001
Penetration assay. The effect of extract RA and antiviral compounds on viral penetration was determined by a modified plaque reduction assay. In contrast to the basic assay, cells were treated with RA after virus attachment to the cell surface. Penetration of IAV during the attachment and treatment phase was prevented by strictly performing all steps at 4°C. MDCK II cells, cultivated to 95% confluence in 12-well culture plates, were pre-cooled to 4°C for 15 min. and washed with PBS. 600 pfu IAV, diluted in PBS (400 µL/well) containing 100 U/mL penicillin, 100 µg/mL streptomycin, 230 µmol/L MgCl₂ and 514 µmol/L CaCl₂, were allowed to attach to the cells. After 20 min. the inoculum was removed, cells were washed with PBS, PBS containing a 2-fold serial dilution of RA was added and cells were incubated for another 30 min. at 4°C. Before shifting culture plates to 37°C for initiation of viral penetration, cells were washed with PBS and covered with serum-free cultivation medium (see above). Following 30 min. incubation at 37°C, medium was removed and cells were treated with low pH citrate buffer (135 mM NaCl, 10 mM KCl, 40 mM citric acid, pH 3.0) for 15 s to stop penetration and inactivate attached, non-penetrated virions. Low pH buffer was removed by washing twice with PBS, and overlay medium was added. Further cultivation and quantitation of plaques was performed as described above. Mock-treatment of attached virus and inactivation of attached mock-treated virus by low pH citrate buffer immediately prior to the 37°C shift served as controls.

Hemagglutination inhibition test (HIT)

Twofold serial dilutions (25 µL) of test compounds in PBS and 4 hemagglutinating units (HU) of IAV (25 µL) were mixed carefully in 96-well plates with U-shaped bottom (Thermo Fisher Scientific Nunc, Schwerte, Germany). Plates were shaken for 5 min. and incubated for 25 min. at room temperature (RT), 50 µL of a 1.5% suspension of newborn chicken erythrocytes (RBC) in PBS (Labor Dr. Merk & Kollegen, Ochsenhausen, Germany) were added, and plates shaken again. Assays were read following a 2 h incubation period at RT, and the minimum inhibitory concentration (MIC), defined as the highest test compound dilution showing complete inhibition of the agglutination of erythrocytes, was determined. In every assay, a test compound control (compound plus RBC without addition of IAV), and erythrocyte controls (A: IAV plus RBC, without addition of test compound; B: RBC, without addition of test compound or IAV) were included. Test results were accepted if the back titration of IAV revealed 4 HU and the controls yielded correct results.

Immunoblotting

The effect of RA or test compounds on IAV envelope proteins was analyzed using recombinant purified HA (20 or 50 µg/mL) of influenza virus A/California/07/2009 (H1N1) (Sino Biological, Beijing, China). SDS-PAGE and blotting was performed essentially as described earlier [21]. To detect IAV HA, membranes were incubated with Anti-IAV H1N1 (Swine Flu 2009) HA antibody (dilution 1: 1000; Sino Biological) or QIAexpress

Table 1. Flavan-3-ols, oligomeric proanthocyanidins, hydrolyzable tannins, depsides and building blocks of tannins tested for antiviral activity.

| no. | compound | source | purity | reference |
|-----|----------|--------|--------|-----------|
| 1   | (+)-catechin monohydrate | Sigma-Aldrich, Steinheim, Germany | ≥98% |          |
| 2   | (-)-epicatechin | Sigma-Aldrich, Steinheim, Germany | ≥90% |          |
| 3   | gallo catechin | IPBP, Münster, Germany | 99% | [51]     |
| 4   | epigallocatechin | IPBP, Münster, Germany | ≥80% | [51]     |
| 5   | epicatechin-3-O-gallate | IPBP, Münster, Germany | ≥95% |          |
| 6   | epigallocatechin-3-O-gallate | Chengdu Biopurify Phytochemicals Ltd, Chengdu, China | ≥95% |          |
| 7   | epicatechin-(4β→8)-epicatechin (procyanidin B2) | IPBP, Münster, Germany | 97% | [24]     |
| 8   | epicatechin-3-O-gallate-(4β→8)-epicatechin-3’-O-gallate (procyanidin B2-di-gallate) | IPBP, Münster, Germany | 91% | [24]     |
| 9   | epicatechin-(4β→8)-epicatechin (procyanidin B5) | IPBP, Münster, Germany | 99% | [24]     |
| 10  | epicatechin-(4β→8)-epicatechin-(4β→8)-epicatechin (procyanidin C7) | IPBP, Münster, Germany | 97% | [24]     |
| 11  | epicatechin-(4β→8)-epicatechin-(4β→8)-epicatechin-(4β→8)-epicatechin (procyanidin D1) | IPBP, Münster, Germany | 100% | [24] |
| 12  | 1,2,3,4,6-penta-O-galloyl-D-glucose (PGG) | IPBP, Münster, Germany | ≥95% | [37]     |
| 13  | geraniin | IPBP, Münster, Germany | ≥95% | [38]     |
| 14  | corilagin | IPBP, Münster, Germany | ≥95% | [38]     |
| 15  | ellagic acid | Roth, Karlsruhe, Germany | ≥95% |          |
| 16  | rosmarinic acid | Sigma-Aldrich, Steinheim, Germany | 97% |          |
| 17  | gallic acid monohydrate | Roth, Karlsruhe, Germany | ≥97% |          |
| 18  | pyrogallol | Merck, Darmstadt, Germany | ≥95% |          |

1 purity was determined by quantitative HPLC (area %), 2 IPBP: Institute of Pharmaceutical Biology and Phytochemistry. doi:10.1371/journal.pone.0110089.t001
Penta-His Antibody (dilution: 1:500; Qiagen, Hilden, Germany) overnight.

Signal transduction assay
90–100% confluent A549 cells in 6-well culture plates were washed with PBS and pretreated with 100 μg/mL RA for 1 h at 37°C, or left untreated. Subsequently, cells were stimulated with EGF (30 ng/mL, 10 min.; R&D Systems, Minneapolis, MN, USA) or TNF-α (20 ng/mL, 30 min.; Sigma-Aldrich) in the presence of RA, or left untreated. Cells were washed with PBS twice and lysed with radioimmunoprecipitation assay buffer (25 mM Tris-HCl [pH 8; Roth], 137 mM NaCl [Merk]; 10% glycerol [MP Biomedicals, Illkirch, France]; 0.1% SDS [Roth]; 0.5% DOC [Roth]; 1% octylphenoxypolyethoxyethanol [IGEPAL; Sigma-Aldrich], 2 mM EDTA [pH 8; Roth]; 50 mM sodium glyceroephosphate [Merck Millipore, Billerica, MA, USA]; 20 mM TSPP [Roth]; plus 1 tablet Complete mini [Roche Diagnostics, Mannheim, Germany] per 10 mL buffer) for 45–60 min. at 4°C. Lysates were cleared by centrifugation, and protein content was quantified by the Bradford method. Briefly, 1 mL of 1:5 diluted protein assay dye reagent concentrate (Bio-Rad Laboratories, Hercules, CA, USA) was added to 5 μL supernatant, absorption at 600 nm was determined and protein content was adjusted to identical levels. Protein expression was analyzed by SDS-PAGE and immunoblot as described above. For protein detection Anti-ERK1/2 (pT202/pY204) antibody (dilution: 1:1000; BD, Franklin Lakes, NJ, USA) or Phospho-NF-κB p65 (Ser536)/93H1) antibody (dilution: 1:1000; Cell Signaling Technology, Danvers, MA, USA) was employed. Loading controls were performed with Anti-α-Tubulin (Clone DM 1A, dilution: 1:500; Sigma-Aldrich) or Anti-β-Actin (Clone AC-15, dilution: 1:1000; Sigma-Aldrich).

Statistical analysis
Data represent the means ± SD of at least three independent experiments. Statistical significance was evaluated by a two-tailed one sample t-test. A P value of <0.05 indicated a statistically significant difference.

**In silico** protein-ligand docking

For in silico analyses the HA of influenza virus A/California/04/2009 (H1N1) [30] (protein data base ID 3LZG) was used. HA of A/California/04/2009 (H1N1) is closely related to HA of the vaccine strain A/California/07/2009 (H1N1) and HAs of IAV(H1N1) pdm09 strains circulating in the post-pandemic era [31,32]. Epicatechin (2), epigallocatechin-3-O-gallate (EGCG) (6), procyanidin B2 (7) and procyanidin B2-di-gallate (8) were docked to the HA of influenza virus in silico by the software Molecular Operating Environment (MOE) version 2011.10 (Chemical Computing Group, Montreal, Canada). After identifying potential binding sites at HA with the MOE module “Site Finder”, the test compounds were docked into the 30 cavities with the best PLB (propensity for ligand binding) score using the MMFF94x force field as implemented in MOE. The flexible docking method (including fit, i.e. both the ligand and the protein binding site were treated as flexible) was applied. The best score of each cavity-compound pair was compared to the best score of the remaining 29 cavities for each of the four compounds. The docking pose represents the best geometry (lowest score) of all investigated orientations of all compounds with respect to all cavities taken into account.

**Results and Discussion**

**Rumex acetosa** extract RA specifically inhibits IAV-infection in cell culture

Extract RA and its constituents were screened for anti-IAV-activity by single cycle, MDCK II cell-based MTTIAV assay. Depending on the IAV isolate, the screening window coefficient Z of the MTTIAV assay ranged from approx. 0.6 to 0.63, indicating that this assay is well suited to detect inhibitors of IAV entry and replication [28,33]. Extract RA exhibited 100% antiviral activity against IAV PR8 at concentrations >5 μg/mL with an IC50 of 2.5 μg/mL. At extract concentrations ≥25 μg/mL a dose-dependent, increasing reduction of cell vitality was observed. The CC50 of extract RA was determined to be approximately 80 μg/mL which corresponds to a selectivity index (SI = CC50/IC50) of 32 (Figure 2A). Almost identical data were found for the clinical isolate I1 of IAV(H1N1)pdm09 with an IC50 of 2.2 μg/mL, and a SI of 36 (Figure 2B). The results obtained by MTTIAV assay were corroborated by plaque reduction assay. At a concentration of 100 ng/mL extract RA reduced plaque formation of IAV(H1N1)pdm09 I1 in a highly significant manner by 67%, at 1 μg/mL by 100% (Figure 3).

The antiviral effect of extract RA was tested in two additional clinical isolates of IAV(H1N1)pdm09 obtained in consecutive samples of a patient with acute respiratory distress syndrome. The oseltamivir-sensitive isolate NRW172 was obtained early after hospitalization, the oseltamivir-resistant isolate NRW173 was isolated after completion of oseltamivir therapy. Extract RA inhibited growth of NRW172 and NRW173 with similar efficiency. The IC50 values determined for NRW172 (19 μg/mL) and NRW173 (37 μg/mL) in MTTIAV assay were approximately 10-fold higher as observed in IAV PR8 and IAV I1 (Figure 2C, D). Previous work indicated that a high protein load of samples may reduce the antiviral activity of extract RA [22]. Since stocks of IAV NRW172 (6.6×106 pfu/mL) and NRW173 (3.3×106 pfu/mL) contained significantly lower virus titers than stocks of IAV PR8 (3.2×106 pfu/mL) and I1 (3.4×106 pfu/mL), inhibitory effects of residual allantoic fluid on the anti-IAV activity of extract RA were studied. Retesting IAV I1 diluted to 6.6×105 pfu/mL in allantoic fluid of a noninfected egg led to an approx. four-fold increase in the IC50 of extract RA (8.2 μg/mL) (Figure S1). Thus, inhibitory effects of residual allantoic fluid on the anti-IAV activity of extract RA appear to account for the differences in IC50 values observed in MTTIAV assay. Accordingly, the consistently lower IC50 values observed in plaque reduction assay are most likely due to higher dilution of virus stocks during incubation with extract RA. Whether strain specific factors also determine the susceptibility of IAV to extract RA as observed for a polyphenolic extract of *Pelargonium sidoides* DC [34] remains to be clarified.

**Structure-activity relationship: epicatechin-3-O-gallate-(4’)→(8)-epicatechin-3’-O-gallate (procyanidin B2-di-gallate) (8)** is responsible for the antiviral activity of RA

The lead compounds in extract RA have been recently described to be flavan-3-ols and oligomeric proanthocyanidins [24]. To pinpoint the plant secondary products responsible for the antiviral effect of the extract, the dominant proanthocyanidins isolated from extract RA were tested for antiviral effects against IAV I1 and cytotoxicity (Table 2) (for numbering of compounds compare Table 1) at concentrations of 2, 20 and 200 μM, respectively, by MTTIAV and cytotoxicity assay.
EGCG (6), a known inhibitor of IAV replication from extracts of green tea which is not present in extract RA [17,24] was included (Table 2).

The monomeric flavan-3-ols catechin (1) and epicatechin (2) did not show antiviral activity. Trihydroxylation of the B-ring in gallocatechin (3) and epigallocatechin (4) led to a slightly increased cytotoxicity. Esterification with gallic acid also increased cytotoxicity. Epicatechin-3-O-gallate (5) did not show antiviral activity, while EGCG (6) exhibited strong activity at concentrations of about 20 μM (estimated SI of 17). These results indicated that an o-trihydroxylation in the B-ring and galloylation at position O-3 is responsible for the antiviral effects of flavan-3-ols detected by MTTIAV assay.

Strong antiviral activity was determined for the oligomeric proanthocyanidins in the cases where the epicatechin building blocks are galloylated. While the dimeric epicatechin-(4β→8)-epicatechin (procyanidin B2) (7) was inactive, the corresponding di-galloylated procyanidin epicatechin-3-O-gallate-(4β→8)-epicatechin-3′-O-gallate (procyanidin B2-digallate) (8) exhibited a prominent antiviral activity (IC_{50} of approx. 15 μM) with an SI of about 13. It should be noted that the increasing cytotoxicity of active compounds such as procyanidin B2-digallate (8) and EGCG (6) at high concentrations reduces the extent of cytoprotection against influenza virus detectable by MTTIAV assay. Using the formula given in Materials and Methods to calculate the results of

Figure 2. Antiviral and cytotoxic activity of RA on MDCK II cells. 1×10^4 pfu IAV/well in serum-free medium (antiviral activity, black bars) or serum-free medium (cytotoxic activity, white bars) were incubated with RA at different concentrations indicated for 1 h at 37°C. 48 h after adding the reaction mixtures to 96-well plates, the antiviral activity and cell vitality were determined by MTTIAV assay and cytotoxicity assay, respectively. The following IAV laboratory strains and isolates were used: (A) laboratory strain PR8 [A/Puerto Rico/8/34], (B) clinical isolate I1 [A(H1N1)pdm09], (C) clinical isolate NRW172 [A(H1N1)pdm09], (D) clinical isolate NRW173 [A(H1N1)pdm09]. Values represent mean ± SD of 3 independent experiments. * p<0.05, ** p<0.01 (two-tailed, unpaired Student’s t-test). Statistical significance of antiviral activity was calculated for nontoxic concentrations only (A: 1 to 10 μg/mL, B: 1 to 7.5 μg/mL, C: 1 to 25 μg/mL, D: 1 to 10 μg/mL).

doi:10.1371/journal.pone.0110089.g002

Procyanidins from Rumex acetosa Inhibit Attachment of Influenza Virus

PLOS ONE | www.plosone.org 6 October 2014 | Volume 9 | Issue 10 | e110089
MTT<sub>IAV</sub> assay, this seemingly reduces the antiviral activity of active compounds at cytotoxic concentrations (200 μM) (Table 2).

Other non-galloylated di- and oligomeric procyanidins from RA with different structural features were inactive. Compared to the epicatechin-(4β→6)-epicatechin (procyanidin B2) (7), dimeric epicatechin procyanidins with 4β→6-interflavan linkage such as epicatechin-(4β→6)-epicatechin (procyanidin B5) (9) did not show an altered antiviral profile. However, the 4β→6-linked compound (9) exerted higher cytotoxicity compared to (7) indicating that changes in the planarity of the molecules may significantly influence the effects on cell physiology. The trimeric and tetrameric procyanidins epicatechin-(4β→6)-epicatechin-(4β→6)-epicatechin (procyanidin C1) (10) and epicatechin-(4β→6)-epicatechin-(4β→6)-epicatechin-(4β→6)-epicatechin (procyanidin D1) (11), respectively, offered no relevant antiviral activity but showed weak cytotoxic effects.

Thus, within the complex mixture of extract RA dominated by flavan-3-ols and proanthocyanidins with different degrees of polymerization and galloylation, the antiviral activity is mostly mediated by galloylated oligomers. The dimeric compound procyanidin B2-di-gallate (8) was assessed as the main principle of antiviral activity in extract RA. The content of procyanidin B2-di-gallate (8) in extract RA was determined by UHPLC to be 0.96%. The strong antiviral effect of procyanidin B2-di-gallate (8) was confirmed by plaque reduction assay (Figure 3). Purified galloylated higher oligomers present in extract RA were not available for antiviral testing, however, most likely are also active against influenza virus. Generally, a higher number of pyrogalloyl moieties, an increased degree of polymerization and a 4β→8 interflavan linkage amplify the anti-IAV activity of polyphenols from extract RA. These findings are in accordance with the results published by De Bruyne et al. (1999) [35] describing similar structural requirements of polyphenols active against HSV and HIV. In addition, trihydroxylation of the B-ring of non-galloylated oligomeric proanthocyanidins has been reported to mediate anti-influenza virus activity [34].

An insignificant anti-influenza activity of the monomeric flavan-3-ols catechin (1) and epicatechin (2) has been reported earlier.

![Figure 3. Reduction of IAV plaque formation by the Rumex acetosa extract RA (A), epigallocatechin-3-O-gallate (6) (B) and procyanidin B2-di-gallate (8) (C). IAV and test compounds were co-incubated for 1 h at 37°C prior to the addition to MDCK II cells. Heparin served as positive control (D). Values (% of plaque reduction) ± SD relate to the respective mock-treated controls ( = 100%). * p<0.05, ** p<0.01 (two-tailed, unpaired Student’s t-test). doi:10.1371/journal.pone.0110089.g003]
| no. | compound                        | cell vitality | anti-IAV activity | IC_{50} (μM) |
|-----|---------------------------------|---------------|-------------------|--------------|
|     |                                 | 2 μM          | 20 μM             | 200 μM       |              |
| 1   | catechin monohydrate            | 105±3         | 102±5             | 119±9        | >200         | >200         |
| 2   | epicatechin                     | 101±2         | 104±4             | 124±20       | >200         | 0±0          | 0±0          | 0±0          | 0±0          | >200         |
| 3   | gallocatechin                   | 106±5         | 108±1             | 75±17        | >200         | 0±0          | 0±0          | 0±0          | 0±0          | 66±5         | ≤156         |
| 4   | epigallocatechin                | 101±4         | 106±1             | 86±17        | >200         | 0±0          | 0±0          | 0±0          | 0±0          | 26±22        | >200         |
| 5   | epicatechin-3-O-gallate         | 107±3         | 106±4             | 41±2         | 175          | 0±0          | 1±0          | 1±0          | 38±2         | ≤258         |
| 6   | epigallocatechin-3-O-gallate    | 103±4         | 92±7              | 62±9         | >200         | 1±1          | 87±25        | 60±7         | ≤12          |
| 7   | procyanidin B2                  | 107±6         | 108±9             | 117±8        | >200         | 0±0          | 0±0          | 1±1          | >200         |
| 8   | procyanidin B2-di-gallate       | 106±5         | 90±3              | 48±4         | 191          | 1±1          | 71±35        | 46±4         | ≤15          |
| 9   | procyanidin B5                  | 100±3         | 84±4              | 57±4         | >200         | 0±0          | 0±0          | 63±4         | ≤163         |
| 10  | procyanidin C1                  | 104±2         | 99±4              | 122±6        | >200         | 0±0          | 0±0          | 87±5         | 123          |
| 11  | procyanidin D1                  | 101±6         | 86±8              | 54±9         | >200         | 0±0          | 1±0          | 44±7         | ≤225         |
| 12  | PGG                             | 91±7          | 57±14             | 37±3         | 83           | 3±3          | 46±9         | 35±1         | ≤22          |
| 13  | geraniin                        | 99±1          | 107±2             | 35±3         | 162          | 0±0          | 1±1          | 25±0         | ≤388         |
| 14  | corilagin                       | 101±1         | 103±1             | 8±1          | 120          | 0±1          | 1±0          | 3±2          | uncalc.³     |
| 15  | ellagic acid                    | 106±1         | 110±3             | 108±2        | >200         | 0±1          | 1±1          | 4±1          | >200         |
| 16  | rosmarinic acid                 | 102±1         | 103±1             | 102±1        | >200         | 0±0          | 0±0          | 1±1          | >200         |
| 17  | gallic acid monohydrate         | 106±5         | 107±8             | 49±18        | 197          | 0±1          | -1±0         | 14±11        | >200         |
| 18  | pyrogallol                      | 98±4          | 96±1              | 43±1         | 176          | 0±0          | 7±3          | 42±1         | ≤241         |

¹ cytotoxicity was determined by cytotoxicity assay.
² antiviral effects against the IAV(H1N1)pdm09 isolate I1 were determined by MTT\_IAV assay.
³ uncalculable due to strong cytotoxicity.
a main constituent from green tea strongly inhibited anti-IAV and IBV in cell culture whereas EGC (4) exhibited little antiviral activity. Yang et al. (2014) [16] found that procyandin B2 (7) significantly inhibited growth of IAV. This is in contrast to our findings where EGC (5) and procyandin B2 (7) were screened negative for anti-IAV activity at noncytotoxic concentrations. Most likely, this reflects differences in the test format used, e.g. MTTIAV assay vs. plaque reduction assay and cytopathic effect inhibition assay, respectively. In particular, the assays used by Song et al. (2005) [19] and Yang et al. (2014) [16] imply multi-cycle replication of IAV and thus should also detect inhibitory effects of compounds on late steps of the viral replication cycle, such as assembly, maturation and release as reviewed by Beeleyel et al. (2015) [28]. Accordingly, Song et al. (2005) [19] detected a direct inhibition of the viral neuraminidase activity by ECG (5), however, not by EGC (4).

A prominent virucidal activity of EGCG (6) from green tea has been first reported by Nakayama et al. (1999) [17]. As reported for EGC (5), EGCG (6) also directly inhibits the viral neuraminidase. In addition to anti-influenza activity, EGCG offers broad anti-infective properties against various viral, bacterial and fungal pathogens as reviewed by Steimann et al. (2012) [15].

After oral application, proanthocyanidins exhibit a very limited bioavailability as reviewed by Zumdick et al. (2012) [36]. Thus, the oral application of active compounds such as procyanidin B2-di-gallate (8) for the systemic treatment of influenza virus infection appears to be inappropriate. As an alternative, the local application of procyandins in the upper respiratory tract, either by lozenges, chewing gums etc. or by inhaling devices allows the active compounds to directly contact the virus and should be preferred.

Because proanthocyanidins are known to have tannin-like effects it might be assumed that these polyphenols from extract RA nonspecifically inactivate essential viral structural proteins. Therefore we included other polyphenols not being part of extracts from R. acetosa, but with known strong astringent activity (Table 1). Pentagalloyl-glucose (PGG) (12), a well characterized hydrolyzable tannin [37], showed moderate antiviral activity, however, significant cell toxicity in the MTTIAV assay (Table 2). Also the ellagitanins geraniin (13), corilagin (14) [38] and ellagic acid (15) were inactive at the highest concentration tested (200 μM) (Table 2). When added at concentrations in the millimolar range, ellagic acid (15) has been reported to exhibit broad anti-influenza activity in vitro and in vivo [39]. The depside rosmaric acid (16), known as tannin-like compound, was also inactive. Keeping in mind that also oligomeric procyanidins such as procyanidin B2, C1 or D1 (7, 10, 11) are known to interact strongly with proteins in a tannin-like manner, nonspecific denaturing effects do not appear to account for most of the antiviral activity observed for procyanidin B2-di-gallate (8). Otherwise, a more potent activity of the hydrolyzable tannins geraniin (13) and corilagin (14) should have been observed. An exception appears to be PGG (12), which exhibited moderate anti-IAV activity in MTTIAV assay with an IC50 of 22 μM. This might be due to its flexible structure. In contrast to geraniin (13), PGG (12) owns the capacity to rotate its gallloyl moieties relatively to the glucose. As a result PGG (12) may be able to bind more strongly to proteins. In accordance with our results, PGG (12) has been recently reported to possess anti-IAV activity at micromolar concentrations and to inhibit viral entry, budding and release [40].

Since only the galloylated compounds (6) and (8) exhibited prominent antiviral activity, we tested the effect of free gallic acid (17) and pyrogallol (18), mimicking a trihydroxylated phenyl system. Both compounds, however, showed only moderate antiviral activity yet relevant cytotoxicity at a concentration of 200 μM. Theisen et al. (2014) [41] recently reported that gallic acid (17) inhibits reporter gene expression of the recombinant IAV laboratory strain A/Puerto Rico/8/1934-NS16-GFP in a multi-cycle assay with an EC50 of approx. 50 μM and a SI of approx. 15. Similar to our findings, however, preincubation of IAV/H1N1/pdm09 particles for 2 h with 50 μg/mL (corresponding to 265 μM) gallic acid (17) had only little effect on virus replication in A549 cells. Furthermore, gallic acid (17) poorly inhibited IAV neuraminidase with an IC50 of 4500 μM. Thus, the inhibitory mechanism of gallic acid (17) on IAV replication remains to be clarified.

Extract RA affects viral attachment
To identify steps in the viral life cycle that were affected by extract RA, virus and cells were treated with extract RA at different times pre and post infection. If pre-treated IAV was added to cells for 1 h, viral replication was inhibited completely at concentrations of extract RA>10 μg/mL. In contrast, if cells were infected with IAV and extract RA was added after 1 h, no antiviral effect was observed at ≤10 μg/mL, indicating that extract RA does not operate in the post-entry phase (data not shown).

To determine whether extract RA interacts with target molecules of the host cells or of the virus, MDCK II cells were incubated with extract RA for 1 h and subsequently infected with IAV. At concentrations of ≤10 μg/mL, this preincubation of the host cells did not result in any antiviral effects (data not shown). This suggests that the anti-IAV activity of extract RA is caused by direct interaction with IAV particles and inhibition of viral entry as shown for a number of polyphenol and tannin-rich plant extracts in earlier reports [17–19,39,41–44].

To reconfirm the effect of extract RA to inhibit penetration of IAV particles already attached to the cell surface we used a penetration assay. Cells were infected at 4°C, unbound viral particles were removed by washing, extract RA was added at 4°C for 30 min., and penetration was allowed to occur by a temperature shift to 37°C (30 min.) followed by washing with pH 3.0 citrate buffer to inactivate non-penetrated virus. As shown in Figure 4, extract RA also blocks viral penetration. However, in comparison to incubation of IAV with extract RA prior to entry, significantly higher concentrations of extract RA were needed to achieve comparable antiviral effects. Washing of cells with pH 3.0 citrate buffer at 4°C immediately after the adsorption period and prior to shifting the temperature to 37°C completely abrogated plaque formation. These observations suggested that RA affects virus entry primarily by inhibiting viral attachment. Similar results were also obtained with EGCG (6) and procyanidin B2-di-gallate (8) (Figure 4). As discussed above, the relatively high protein load due to the presence of cells and culture media components may increase the concentration of RA and its active constituents needed to inhibit penetration of IAV already attached to the cell surface. When added after the infection of MDCK cells, high concentrations of green tea extract and EG (4) have been reported to affect the early phase of influenza virus infection, possibly by interference of the polyphenolic compounds with the acidification of endosomes [10].

RA and galloylated oligomeric procyanidins interact with IAV hemagglutinin
Data presented above suggested that extract RA, EGCG (6) and procyanidin B2-di gallate (8) may interfere with the sialic acid receptor binding function of the viral HA. Therefore, effects on
HA-mediated attachment of IAV to the cell surface were further investigated in a hemagglutination inhibition assay. Using four hemagglutinating units of IAV[H1N1]pdm09 I1 in allantoic fluid (5.5 x 10⁵ pfu/mL) to agglutinate chicken erythrocytes, pretreatment of the IAV suspension with extract RA inhibited erythrocyte agglutination at a minimum inhibitory concentration of 156 μg/mL (Table 3). At higher concentrations, hemagglutination reappeared due to direct agglutination of erythrocytes by extract RA. By serial dilution of extract RA in PBS the minimal concentration needed to agglutinate erythrocytes in the absence of IAV was determined to be 156 μg/mL. Thus, treatment of IAV with extract RA appears to directly interfere with the cell surface receptor-binding function of IAV HA. Procyanidin B2-di-gallate (8) did not inhibit IAV-mediated hemagglutination, however, was able to directly agglutinate erythrocytes at a concentration ≥39 μM. In accordance to Theissen et al. (2014) [41] EGCG (6) showed no inhibitory effect on IAV-mediated hemagglutination, however, directly agglutinated erythrocytes (Table 3). None of the test compounds induced hemolysis (data not shown). Strong, IAV-strain specific differences in the concentrations of EGCG (6) needed to inhibit hemagglutination have been reported earlier [19], and may account for the failure to detect inhibitory effects of procyanidin B2-di-gallate (8) and EGCG (6) on IAV[H1N1]pdm09 induced hemagglutination.

In addition, the physical interaction of extract RA and its active compounds with recombinant, soluble HA was studied by SDS-PAGE and immunoblotting. Incubation of HA with high concentrations of extract RA (A), epigallocatechin-3-O-gallate (6) (B) and procyanidin B2-di-gallate (8) (C) on the penetration of IAV. Effects on the penetration of IAV were determined by a modified plaque reduction assay. Test compounds were added for 30 min. after attachment of IAV to MDCK II cells at 4°C. Values (% of plaque reduction) ± SD relate to the respective mock-treated controls (= 100%) and represent ≥3 independent experiments. * p<0.05, ** p<0.01 (two-tailed, unpaired Student’s t-test).

doi:10.1371/journal.pone.0110089.g004

Table 3. Effect of Rumex acetosa extract RA and single compounds on IAV-mediated hemagglutination.

| compound          | MIC       | direct agglutination | highest concentration tested |
|-------------------|-----------|----------------------|------------------------------|
| Rumex acetosa extract | 156 μg/mL | 156 μg/mL            | 10 mg/mL                     |
| epigallocatechin-3-O-gallate (6) | n.d.²  | 156 μM          | 5 mM                         |
| procyanidin B2-di-gallate (8) | n.d.    | 39 μM           | 5 mM                         |

¹compounds are numbered as given in Table 1,
²n.d.: not detectable.

doi:10.1371/journal.pone.0110089.t003
galloylation enhances the binding of proanthocyanidins to HA. As bioassays: An increase in the degree of polymerization and further corroborate the observation depicted in the functional better docking score than the monomeric (8). Inspection of the best docking pose revealed the binding of (7) with both galloyl moieties and the B-ring of the second epicatechin gallate unit deep inside the sialic acid binding pocket, (Figure 7) with both galloyl moieties and the B-ring of the second epicatechin gallate unit deep inside the sialic acid binding pocket, with (8) showing the best score. The data demonstrated a better score of galloylated compounds in comparison to the respective ungalloylated molecules. Similar results were observed with an HA-specific monoclonal antibody (data not shown). The effects of high concentrations of extract RA and its active compounds on HA are in good accordance with the model suggested by Hasham (1996) [45] by describing the aggregation of proteins by polyphenols, and confirms earlier findings in HSV-1 [21]. On the other hand, antiviral effects of (6) and (8) are detectable at much lower concentrations. Therefore, similar to what was observed for RA, tannin-like astringent effects are unlikely to mediate most of the antiviral activity of these compounds.

Procyanidin B2-di-gallate (8) is predicted in silico to interact with the sialic acid binding site of viral hemagglutinin

To visualize the binding of components from RA to the viral surface proteins, four selected compounds were docked to HA of influenza virus A/California/04/2009 (H1N1) [30] in silico by means of the software package MOE. Exemplary for the docking results of all investigated cavities of HA, the score of the docking at the sialic acid binding site [46] was −6.29 for procyanidin B2-di-gallate (8), −5.55 for procyanidin B2 (7), −5.89 for EGCG (6), and −5.28 for epicatechin (2), with (8) showing the best score. The data demonstrated a better score of galloylated compounds in comparison to the respective ungalloylated molecules. Additionally, inspection of the best docking pose revealed the binding of (8) (Figure 7) with both galloyl moieties and the B-ring of the second epicatechin gallate unit deep inside the sialic acid binding pocket, suggesting a notably stronger anchorage of galloylated molecules in contrast to ungalloylated compounds and offering a straightforward explanation for the strong activity of this digalloylated dimer. Aside from this, the investigated dimers (7) and (8) yielded a better docking score than the monomeric (6) and (2). These results further corroborate the observation depicted in the functional bioassays: An increase in the degree of polymerization and galloylation enhances the binding of proanthocyanidins to HA. As discussed already above, these results are in contrast to a model favoring the unspecific “coating” of HA by polyphenols. The strong anchoring of the galloylated compounds (6) and (8) in the sialic acid binding pocket of HA disclosed by in silico visualization may block the receptor binding site of HA and consequently specifically inhibit the viral adsorption process.

EGCG (6) blocks binding of HIV gp120 to its cellular receptor CD4, and it has been suggested that there is an appropriate binding site of EGCG (6) in the region of CD4 interacting with gp120. The galloyl ring D of EGCG (6) appears to stack against aromatic and basic amino acid side chains within the gp120 binding site of CD4, e.g., Phe 43, Arg 59, Trp62 of CD4, thereby abrogating interaction of gp120 with CD4 [47]. Notably, crystal structure analyses revealed that a subgroup of neutralizing antibodies interferes with receptor binding of HA by targeting the highly conserved Tyr98 and Trp153 at the hydrophobic cavity base of the sialic acid binding site with an aromatic side chain [48,49]. It is therefore worth mentioning that in our docking model, the galloyl moiety of the second epicatechin gallate unit of procyanidin B2-di-gallate (8) is close to the aromatic side chain of Trp153 in the sialic acid binding pocket of HA, where it might interact in terms of a T-shaped π-π interaction. Furthermore, the B-ring of the second subunit is in a position where its phenolic oxygens might form hydrogen bonds with the hydroxyl proton of Tyr98 (both distances O...H<3 A; see Figure 7B).

RA does not interfere with cellular responses to TNF-α and EGF

While the extract RA showed little cytotoxic effect over a wide range of concentrations it might still elicit or interfere with intracellular responses in treated cells. Thus, the effect of the addition of high concentrations of RA (100 μg/mL) close to the calculated CC_50 for 1 h at 37°C on TNF-α and EGF induced signal transduction was studied. As shown in Figure 8A stimula-
tion of A549 cells by TNF-α led to similar increases in phosphorylated NF-κB (pNF-κB) in RA-treated or mock-treated cells, respectively. In the absence of TNF-α, neither RA nor mock-treatment led to a significant induction of pNF-κB. Potential effects of RA on Raf/MEK/ERK-signaling were investigated by stimulation of A549 cells by EGF (Figure 8B). While non-EGF-stimulated cells did not express pERK1/2, regardless if pretreated with RA or not (lanes 1 and 3), EGF treatment activated its expression (lane 2). Pretreatment of the cells with RA, followed by stimulation with EGF did not result in a significant decrease in pERK1/2 expression. It was thus concluded that even high concentrations of RA close to the CC50 are unlikely to significantly elicit or interfere with TNF-α and EGF-induced signal transduction. This is in accordance to recent results showing that cells are inert to LADANIA067, a polyphenol-rich extract of Ribes nigrum folium inhibiting entry of IAV [50].

Conclusions

The proanthocyanidin-enriched extract RA and its main active constituent epicatechin-3-O-gallate-(4β-R8)-epicatechin-3'-O-gallate protect cells from IAV infection by blocking IAV adsorption and interfering with penetration at higher concentrations. Anti-IAV-activity is dependent on galloylation of the procyanidin backbone. At effective concentrations, cells are unaffected by RA and procyanidin B2-di-gallate. Regarding the need for new and abundantly available anti-influenza therapeutics, RA and procyanidin B2-di-gallate appear to be a promising expansion of the currently available anti-influenza agents.

Supporting Information

Figure S1 Inhibitory effect of residual allantoic fluid on the antiviral activity of RA. To demonstrate that titres of viral stocks prepared from allantoic fluid of infected eggs have an impact on the outcome of the MTTIAV assay, stocks of isolate 11 (H1N1)pdm09 were approx. 50-fold prediluted in allantoic fluid (from 3.2×10^6 pfu/mL to 6.6×10^4 pfu/mL). Subsequently, virus was diluted to 1×10^4 pfu IAV/well in serum-free medium and the antiviral activity and cell vitality were determined by MTTIAV and cytotoxicity assay, respectively (compare Figure 2). Values represent mean ± SD of ≥3 independent experiments, * p<0.05, ** p<0.01 (two-tailed, unpaired Student’s t-test). Statistical significance of antiviral activity was calculated for nontoxic concentrations only (1 to 5 μg/mL).

(TIF)
Acknowledgments

The expert technical assistance of Maria Hovens and Marie-Luise Romberg is highly acknowledged.

Author Contributions

Conceived and designed the experiments: AD AH WH TJS CE SL JK. Performed the experiments: AD AH WH TJS CE SL JK. Analyzed the data: AD AH WH TJS CE SL JK. Contributed reagents/materials/analysis tools: WH TJS CE SL JK. Wrote the paper: AD AH WH TJS CE SL JK.

References

1. Lambert LC, Fauci AS (2010) Influenza vaccines for the future. N Engl J Med 363: 2036–2044.
2. Taubenberger JK, Morens DM (2006) 1918 Influenza: the mother of all pandemics. Emerg Infect Dis 12: 15–22.
3. Kamali A, Holodny M (2013) Influenza treatment and prophylaxis with neuraminidase inhibitors: a review. Infect Drug Resist 6: 187–196.
4. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, et al. (2011) Antiviral agents for the treatment and chemoprophylaxis of influenza — recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 60: 1–24.
5. Thoelen K, Awad T, Boitin G, Thabane L (2011) Systematic review of influenza resistance to the neuraminidase inhibitors. BMC Infect Dis 11: 134.
6. Dixit R, Khandaker G, Ilgoutz S, Rashid H, Booy R (2013) Emergence of oseltamivir resistance: control and management of influenza before, during and after the pandemic. Infect Dis Disord Targets 15: 34–45.
7. De Clercq E (2013) Antivirals: past, present and future. Biochem Pharmacol 85: 727–744.
8. De Clercq E (2013) A Cutting Edge View on the Current State of Antiviral Drug Development. Med Res Rev 33: 1249–1277.
9. Laursen NS, Wilson IA (2013) Broadly neutralizing antibodies against influenza viruses. Antiviral Res 90: 476–483.
10. Wang X, Jia W, Zhao A, Wang N (2006) Anti-influenza agents from plants and traditional Chinese medicine. Phytother Res 20: 335–341.
11. Ge H, Wang YF, Xu J, Gu Q, Liu HB, et al. (2010) Anti-influenza agents from Traditional Chinese Medicine. Nat Prod Rep 27: 1756–1780.
12. Jassim SA, Naji MA (2003) Novel antiviral agents: a medicinal plant perspective.
13. Appl Microbiol 95: 412–427.
14. Dagla M (2012) Polyphenols as antimicrobial agents. Curr Opin Biotechnol 23: 174–181.
15. Song JM, Seong BL (2007) Tea catechins as a potential anti-viru
16. Acknowledgments

The expert technical assistance of Maria Hovens and Marie-Luise Romberg is highly acknowledged.

Author Contributions

Conceived and designed the experiments: AD AH WH TJS CE SL JK. Performed the experiments: AD AH WH TJS CE SL JK. Analyzed the data: AD AH WH TJS CE SL JK. Contributed reagents/materials/analysis tools: WH TJS CE SL JK. Wrote the paper: AD AH WH TJS CE SL JK.

References

1. Lambert LC, Fauci AS (2010) Influenza vaccines for the future. N Engl J Med 363: 2036–2044.
2. Taubenberger JK, Morens DM (2006) 1918 Influenza: the mother of all pandemics. Emerg Infect Dis 12: 15–22.
3. Kamali A, Holodny M (2013) Influenza treatment and prophylaxis with neuraminidase inhibitors: a review. Infect Drug Resist 6: 187–196.
4. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, et al. (2011) Antiviral agents for the treatment and chemoprophylaxis of influenza — recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 60: 1–24.
5. Thoelen K, Awad T, Boitin G, Thabane L (2011) Systematic review of influenza resistance to the neuraminidase inhibitors. BMC Infect Dis 11: 134.
6. Dixit R, Khandaker G, Ilgoutz S, Rashid H, Booy R (2013) Emergence of oseltamivir resistance: control and management of influenza before, during and after the pandemic. Infect Dis Disord Targets 15: 34–45.
7. De Clercq E (2013) Antivirals: past, present and future. Biochem Pharmacol 85: 727–744.
8. De Clercq E (2013) A Cutting Edge View on the Current State of Antiviral Drug Development. Med Res Rev 33: 1249–1277.
9. Laursen NS, Wilson IA (2013) Broadly neutralizing antibodies against influenza viruses. Antiviral Res 90: 476–483.
10. Wang X, Jia W, Zhao A, Wang N (2006) Anti-influenza agents from plants and traditional Chinese medicine. Phytother Res 20: 335–341.
11. Ge H, Wang YF, Xu J, Gu Q, Liu HB, et al. (2010) Anti-influenza agents from Traditional Chinese Medicine. Nat Prod Rep 27: 1756–1780.
12. Jassim SA, Naji MA (2003) Novel antiviral agents: a medicinal plant perspective.
13. Appl Microbiol 95: 412–427.
14. Dagla M (2012) Polyphenols as antimicrobial agents. Curr Opin Biotechnol 23: 174–181.
15. Song JM, Seong BL (2007) Tea catechins as a potential anti-virus...